Enterprise Therapeutics selected as a finalist for Scrip Awards and Lifestars Awards

  • Scrip Awards 2018 “Financing Deal of the Year- Private” category
  • Lifestars Awards 2018 “EU Private Finance Raise of the Year <£30M” category

Brighton, UK – 02 October 2018: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has recently been announced as a finalist in the “Financing Deal of the Year” category for the Scrip Awards, and the “EU Private Finance Raise of the Year- <£30M” category of LSX’s Lifestars Awards, based on its oversubscribed £29 million ($41 million USD) Series B funding round.


Enterprise announced the closing of its Series B round in April 2018. The round was co-led by Versant Ventures and Novartis Venture Fund, and the syndicate also included new investor Forbion, founding investor Epidarex Capital, and existing investor IP Group. The investment will fund the Company’s drug discovery pipeline of muco-regulatory therapies into clinical development, with the aim of enabling new treatment options for cystic fibrosis, chronic obstructive pulmonary disease and severe asthma.


The Scrip Awards recognise both individual and corporate achievement across a wide range of industry activities, including novel deals, new drug launches and technological breakthroughs in clinical trials. Winners will be announced on 28th November at the Gala Dinner in London.


The Lifestars Awards celebrate the success, innovations and transformational deals advancing the industry over the past year. The awards ceremony is run by LSX (formerly known as Biotech and Money) in association with Jefferies, on the evening of 13th November. The awards form the evening network function of the Jefferies Annual Healthcare Conference in London, Europe’s largest healthcare investment banking conference.


Dr John Ford, CEO, Enterprise Therapeutics, commented: “The Series B investment, along with the additional scientific, development and biotech expertise held by new directors, means that Enterprise is incredibly well positioned to achieve its longer-term goals of bringing new respiratory medicines to market. We are delighted that our significant progress has been recognised by these two very credible and prestigious industry awards.”


For more information about the Scrip Awards 2018, visit: https://pharmaintelligence.informa.com/events/awards/scrip-awards-2018

For more information about the Lifestars Awards 2018, visit: https://www.lsxleaders.com/lifestars-awards